新型生物标志物在病毒性肺炎中的应用研究进展

Application advances of novel biomarkers in viral pneumonia

在当前新型冠状病毒广泛传播的背景下,病毒性肺炎再次引起重视,据保守估计,全球成人病毒性肺炎每年至少发生1亿例。呼吸道病毒被认为是成人近1/3社区获得性肺炎的病原体,特别是流感病毒(A和B)、鼻病毒、副流感病毒1、2和3,呼吸道合胞病毒,腺病毒以及冠状病毒。就新型冠状病毒肺炎疫情带来的启示而言,新型呼吸道病毒的早发现、早处理对人类健康非常重要。近些年来,与病毒性肺炎相关的生物标志物表现出良好的诊断效能,这些生物标志物的单独或联合检测为病毒性肺炎早期诊断和预后评估带来新的机遇。本文对病毒性肺炎的相关新型生物标志物的研究进展进行系统阐述。

With the Background of current global widespread coronavirus disease 2019(COVID-19),viral pneumonia has attracted our attention once again.In conservative estimates there are at least 100 million cases of adult viral pneumonia occur globally happened each year.Nearly one-third of pathogen in community-acquired pneumonia in adults were identified as respiratory viruses,particularly influenza viruses(A and B),rhinoviruses,parainfluenza viruses 1,2,3,respiratory syncytial viruses,adenoviruses,and coronavirus.In terms of the implications of the COVID-19,early detection and treatment of novel respiratory viruses is paramount for human health.In recent years,biomarkers related to viral pneumonia have shown good diagnostic efficacy,it brings new opportunities for the early diagnosis and prognosis evaluation of viral pneumonia that by alone or in combination with these biomarkers.This review will formulize the research progress of novel biomarkers related to viral pneumonia.